Phase II Study Update of Brentuximab Vedotin in Patients with Relapsed/Refractory Systemic ALCL


Phase II Study Update of Brentuximab Vedotin in Patients with Relapsed/Refractory Systemic ALCL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/11/12)

Advani RH et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update. Proc ASH 2011;Abstract 443.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.